# US 2012/0252884 A1 · Modified and Stabilized GDF Propeptides and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252884 A1
- Document ID: US20120252884A1
- Status: Published application
- Kind: A1
- Application number: 13/523,391
- Filed: 2012-06-14
- Published: 2012-10-04
- Earliest claimed: 2001-02-08
- Assignees: Wyeth
- Inventors: Neil M. Wolfman; Soo-Peang Khor; Kathleen N. Tomkinson
- Web page: https://patentgrep.com/patent/US20120252884A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C07K 14/51: Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- C07K 16/18: against material from animals or humans
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).

## Claims

### Claim at position 1

1-118. (canceled)

### Claim 119

A nucleic acid molecule encoding a GDF-8 propeptide comprising a nucleic acid sequence that is at least 95% identical to SEQ ID NO:6 and encodes a propeptide that is modified at the aspartate residue corresponding to aspartate 76 of SEQ ID NO:5.

### Claim 120

A nucleic acid molecule encoding a GDF-8 propeptide comprising a nucleic acid that hybridizes under stringent hybridization conditions (hybridization at 65° in 6×SSC) to the complement of SEQ ED NO:6 and encodes a propeptide that is modified at the aspartate residue corresponding to aspartate 76 of SEQ ID NO:5, wherein the encoded propeptide inhibits at least one GDF-8 biological activity.

### Claim 121 (depends on 120)

The nucleic acid of claim 120, wherein the GDF-8 propeptide negatively regulates skeletal muscle mass.

### Claim 122 (depends on 119)

A pharmaceutical composition comprising the nucleic acid of claim 119 and a pharmaceutically acceptable carrier or vector.

### Claim 123 (depends on 119)

A vector comprising the nucleic acid of claim 119.

### Claim 124 (depends on 120)

A vector comprising the nucleic acid of claim 120.

### Claim 125 (depends on 123)

The vector of claim 123 further comprising a nucleic acid that encodes an Fc region of an IgG molecule.

### Claim 126 (depends on 125)

The vector of claim 125 further comprising a linker peptide between the nucleotides encoding the GDF-8 propeptide and the IgG Fc region.

### Claim 127 (depends on 126)

The vector of claim 126, wherein the linker peptide comprises nucleotides encoding for the amino acid sequence consisting of glycine-serine-glycine-serine (GSGS) (SEQ ID NO: 17).

### Claim 128 (depends on 120)

A host cell comprising the vector of claim 120.

### Claim 129 (depends on 119)

The method of making a GDF-8 propeptide that has been modified at the aspartate residue corresponding to aspartate 76 of SEQ ID NO:5 comprising:
(a) preparing a nucleic acid molecule according to claim 119;
(b) preparing a nucleic acid molecule encoding the Fc region of the IgG molecule; and
(c) fusing the nucleic acid molecules from steps (a) and (b) to produce a modified GDF-8 propeptide.

### Claim 130 (depends on 129)

The method of claim 129, further comprising preparing a double stranded oligonucleotide encoding a linker peptide and fusing the cDNA molecules from steps (a) and (b) to either end of the double stranded oligonucleotide encoding the linker peptide.

### Claim 131 (depends on 130)

The method of claim 130, wherein the linker peptide comprises the amino acid sequence consisting of glycine-serine-glycine-serine (GSGS).

### Claim 132 (depends on 122)

The pharmaceutical composition of claim 122, wherein the vector is a viral vector.

### Claim 133 (depends on 123)

The vector of claim 123, wherein the vector is a viral vector.
